Market Research Logo

Global Pharmacovigilance Market Analysis and Forecast, 2015-2022

Global Pharmacovigilance Market Analysis and Forecast, 2015-2022

Global Pharmacovigilance Market Analysis and Forecast, 2015-2022


Executive Summary
1 Research Scope and Methodology
1.1 Scope of the Report
1.2 The Global Pharmacovigilance Market Research Methodology
1.2.1 Research Methodology for Case Processing Cost FTE/HR Calculation
1.2.2 Primary Data Sources
1.2.3 Secondary Data Sources
1.3 Assumptions and Limitations for Market Estimation and FTE Pricing
1.3.1 Assumptions
1.3.2 Limitations
2 Market Overview
2.1 Need for Pharmacovigilance
2.2 Benefits of Pharmacovigilance
2.3 Reporting in Pharmacovigilance
2.4 Pharmacovigilance Service Types
2.5 Outsourcing Pricing Delivery Models
2.6 Applications for Pharmacovigilance
3 Market Dynamics
3.1 Market Drivers
3.1.1 Increase in Drug Consumption due to rise in Chronic Illness
3.1.2 Evolving Drug Safety Regulations and Safety Issues
3.1.3 High Data Volumes of Adverse Events
3.1.4 Role of Emerging Markets in Driving Pharmacovigilance
3.1.5 Emergence of Social Media and Digital Health
3.2 Challenges
3.2.1 Globalization
3.2.2 Web Based Sales and Information
3.2.3 Broader Safety Concerns
3.2.4 Public Health versus Pharmaceutical Industry Economic Growth
3.2.5 Data Privacy
3.3 Opportunities in Pharmacovigilance
3.3.1 Proactive Pharmacovigilance
3.3.2 Personalized Medicines
3.3.3 Innovations and Advancements in Technologies
3.3.4 Database Analytics
4 Competitive Landscape
4.1 Key Development Strategies
4.1.1 Mergers and Acquisitions
4.1.2 Product Development and Launches
4.1.3 Partnerships, Collaborations and Agreements
4.1.4 Business Expansions
4.1.5 Awards and Recognitions
4.2 Industry Attractiveness
5 Industry Analysis
5.1 Regulatory Agencies
5.2 Consortiums and Agencies
5.3 Patents
5.4 Value Chain Analysis
6 Global Pharmacovigilance Market Analysis & Forecast by Clinical Trials Insights
6.1 Market Overview
6.2 Preclinical Trial
6.2.1 Market Overview
6.3 Phase I Clinical Trial
6.3.1 Market Overview
6.4 Phase II Clinical Trial
6.4.1 Market Overview
6.5 Phase III Clinical Trial
6.5.1 Market Overview
6.6 Phase IV Clinical Trial
6.6.1 Market Overview
7 Global Pharmacovigilance Market Analysis & Forecast by Service Provider Type
7.1 Market Overview
7.2 In-House Pharmacovigilance
7.2.1 Market Overview
7.3 Outsourcing Pharmacovigilance
7.3.1 Market Overview
8 Global Pharmacovigilance Market Analysis & Forecast by Geography
8.1 Market Overview
8.2 North America
8.2.1 Market Overview
8.2.2 U.S.
8.2.3 Canada
8.3 Europe
8.3.1 Market Overview
8.3.2 United Kingdom (U.K.)
8.3.3 Germany
8.3.4 France
8.3.5 Italy
8.3.6 Spain
8.3.7 Others
8.4 Asia Pacific (APAC)
8.4.1 Market Overview
8.4.2 India
8.4.3 Japan
8.4.4 China
8.4.5 Korea
8.4.6 Others
8.5 Rest of the World (RoW)
8.5.1 Market Overview
9 Company Profiles
9.1 PrimeVigilance
9.1.1 Company Overview
9.1.2 Global Footprint
9.1.3 PV Case Processing Snapshot
9.2 Accenture
9.2.1 Company Overview
9.2.2 Global Footprint
9.2.3 PV Case Processing Snapshot
9.3 4C Pharma Solutions
9.3.1 Company Overview
9.3.2 Global Footprint
9.3.3 PV Case Processing Snapshot
9.4 PharSafer Associates
9.4.1 Company Overview
9.4.2 Global Footprint
9.4.3 PV Case Processing Snapshot
9.5 Clinquest
9.5.1 Company Overview
9.5.2 Global Footprint
9.5.3 PV Case Processing Snapshot
9.6 iMEDGlobal Corporation
9.6.1 Company Overview
9.6.2 Global Footprint
9.6.3 PV Case Processing Snapshot
9.7 InVentiv Health Clinical
9.7.1 Company Overview
9.7.2 Global Footprint
9.7.3 PV Case Processing Snapshot
9.8 United BioSource Corporation (UBC)
9.8.1 Company Overview
9.8.2 Global Footprint
9.8.3 PV Case Processing Snapshot
9.9 Parexel
9.9.1 Company Overview
9.9.2 Global Footprint
9.9.3 PV Case Processing Snapshot
9.10 PPD
9.10.1 Company Overview
9.10.2 Global Footprint
9.10.3 PV Case Processing Snapshot
9.11 Apcer LifeSciences
9.11.1 Company Overview
9.11.2 Global Footprint
9.11.3 PV Case Processing Snapshot
9.12 iSafety Systems
9.12.1 Company Overview
9.12.2 Global Footprint
9.12.3 PV Case Processing Snapshot
9.13 4G Pharmacovigilance
9.13.1 Company Overview
9.13.2 Global Footprint
9.13.3 PV Case Processing Snapshot
9.14 Redline Pharmacovigilance
9.14.1 Company Overview
9.14.2 Global Footprint
9.14.3 PV Case Processing Snapshot
9.15 Oviya Medsafe
9.15.1 Company Overview
9.15.2 Global Footprint
9.15.3 PV Case Processing Snapshot
9.16 ProductLife Group (PLG)
9.16.1 Company Overview
9.16.2 Global Footprint
9.16.3 PV Case Processing Snapshot
9.17 Lindeq
9.17.1 Company Overview
9.17.2 Global Footprint
9.17.3 PV Case Processing Snapshot
9.18 Voisin Consulting LifeSciences (VCLS)
9.18.1 Company Overview
9.18.2 Global Footprint
9.18.3 PV Case Processing Snapshot
9.19 Ecron Acunova
9.19.1 Company Overview
9.19.2 Global Footprint
9.19.3 PV Case Processing Snapshot
9.20 Cmed Group
9.20.1 Company Overview
9.20.2 Global Footprint
9.20.3 PV Case Processing Snapshot
9.21 Regulis Consulting
9.21.1 Company Overview
9.21.2 Global Footprint
9.21.3 PV Case Processing Snapshot
9.22 NDA Group
9.22.1 Company Overview
9.22.2 Global Footprint
9.23 Synowledge
9.23.1 Company Overview
9.23.2 Global Footprint
9.23.3 PV Case Processing Snapshot
9.24 Prosar
9.24.1 Company Overview
9.24.2 Global Footprint
9.24.3 PV Case Processing Snapshot
9.25 Premier Research
9.25.1 Company Overview
9.25.2 Global Footprint
9.25.3 PV Case Processing Snapshot
9.26 Medpace
9.26.1 Company Overview
9.26.2 Global Footprint
9.26.3 PV Case Processing Snapshot
9.27 Vigilex
9.27.1 Company Overview
9.27.2 Global Footprint
9.27.3 PV Case Processing Snapshot
9.28 Sciformix
9.28.1 Company Overview
9.28.2 Global Footprint
9.28.3 PV Case Processing Snapshot
9.29 Symogen
9.29.1 Company Overview
9.29.2 Global Footprint
9.29.3 PV Case Processing Snapshot
9.30 RxLogix
9.30.1 Company Overview
9.30.2 Global Footprint
9.30.3 PV Case Processing Snapshot
9.31 Drug Safety Alliance
9.31.1 Company Overview
9.31.2 Global Footprint
9.31.3 PV Case Processing Snapshot
9.32 Quintiles
9.32.1 Company Overview
9.32.2 Global Footprint
9.32.3 PV Case Processing Snapshot
9.33 Sentrx Safety Solutions
9.33.1 Company Overview
9.33.2 Global Footprint
9.33.3 PV Case Processing Snapshot
9.34 Tata Consultancy Services (TCS)
9.34.1 Company Overview
9.34.2 Global Footprint
9.34.3 PV Case Processing Snapshot
9.35 ICON plc
9.35.1 Company Overview
9.35.2 Global Footprint
9.35.3 PV Case Processing Snapshot
9.36 Covance
9.36.1 Company Overview
9.36.2 Global Footprint
9.36.3 PV Case Processing Snapshot
9.37 PRA Health Sciences
9.37.1 Company Overview
9.37.2 Global Footprint
9.37.3 PV Case Processing Snapshot
9.38 Cognizant
9.38.1 Company Overview
9.38.2 Global Footprint
9.38.3 PV Case Processing Snapshot
9.39 Bristol-Myers-Squibb
9.39.1 Company Overview
9.39.2 Global Footprint
9.40 GlaxoSmithKline
9.40.1 Company Overview
9.40.2 Global Footprint
9.41 Sanofi
9.41.1 Company Overview
9.41.2 Global Footprint
9.42 Pfizer
9.42.1 Company Overview
9.42.2 Global Footprint
9.43 Roche
9.43.1 Company Overview
9.43.2 Global Footprint
List of Tables
Table 1 Case Processing Organizations Classification
Table 1.1 Sample FTE/Hour Cost Calculation Sheet
Table 2.1 Indicators to Measure ADRs
Table 2.2 Detection and Prevention of Adverse Events
Table 4.1 Mergers in Pharmacovigilance Market (2014-16)
Table 4.2 Acquisitions in Pharmacovigilance Market (2014-16)
Table 4.3 Latest Product Launches in Pharmacovigilance Market (2013-16)
Table 4.4 Key Partnerships and Collaborations in Pharmacovigilance Industry (2014-16)
Table 4.5 Key Expansions in Pharmacovigilance Industry (2013-16)
Table 4.6 Awards and Recognitions to Pharmacovigilance Companies (2013-16)
Table 4.7 Buyers and Suppliers in Global Pharmacovigilance Market
Table 4.8 Key Factors considered for threat from New Entrants in Global Pharmacovigilance Market
Table 4.9 Key Factors Affecting Bargaining Power of Buyers in the Global Pharmacovigilance Market
Table 4.10 Key Factors affecting the Bargaining Power of Suppliers in the Global Pharmacovigilance Market
Table 4.11 Key Factors affecting threat of Substitute Products or Services in the Global Pharmacovigilance Market
Table 4.12 Key Factors determining Rivalry among Existing Firms in the Global Pharmacovigilance Market
Table 5.1 Prominent Regulatory Agencies Region wise Working for Pharmacovigilance
Table 5.2 List of Consortiums and Agencies active in the Pharmacovigilance Industry
Table 5.3 List of Patents in Pharmacovigilance Market (2014-16)
Table 6.1 Clinical Trial Safety Monitoring Key Stakeholders
Table 6.2 Key Drugs Safety Issues
Table 6.4 Pharmacovigilance Market by Clinical Trials Insights, 2015-
Table 6.5 Pharmacovigilance Market Value for Preclinical Trials Insight by Service Provider Type, 2015-
Table 6.6 Pharmacovigilance Market Value for Preclinical Trials Insight by Geography, 2015-
Table 6.7 Pharmacovigilance Market Value for Phase I Clinical Trials Insight by Service Provider Type, 2015-
Table 6.8 Pharmacovigilance Market Value for Phase I Clinical Trials Insight by Geography, 2015-
Table 6.9 Pharmacovigilance Market Value for Phase II Clinical Trials Insight by Service Provider Type, 2015-
Table 6.10 Pharmacovigilance Market Value for Phase II Clinical Trials Insight by Geography, 2015-
Table 6.11 Pharmacovigilance Market Value for Phase III Clinical Trials Insight by Service Provider Type, 2015-
Table 6.12 Pharmacovigilance Market Value for Phase III Clinical Trials Insight by Geography, 2015-
Table 6.13 Pharmacovigilance Market Value for Phase IV Clinical Trials Insight by Service Provider Type, 2015-
Table 6.14 Pharmacovigilance Market Value for Phase IV Clinical Trials Insight by Geography, 2015-
Table 7.1 Pharmacovigilance Market Value by Service Provider Type, 2015-
Table 7.2 In-House Pharmacovigilance Market Value by Clinical Trials Insights, 2015-
Table 7.3 In-House Pharmacovigilance Market Value by Geography, 2015-
Table 7.4 Outsource Pharmacovigilance Market Value by Clinical Trial, 2015-
Table 7.5 Outsource Pharmacovigilance Market Value by Geography, 2015-
Table 8.1 North America Pharmacovigilance Market Value by Clinical Trials, 2015-
Table 8.2 North America Pharmacovigilance Market Value by Service Provider Type, 2015-
Table 8.3 Europe Pharmacovigilance Market Value by Clinical Trials, 2015-
Table 8.4 Europe Pharmacovigilance Market Value by Service Provider Type, 2015-
Table 8.5 APAC Pharmacovigilance Market Value by Clinical Trials, 2015-
Table 8.6 APAC Pharmacovigilance Market Value by Service Provider Type, 2015-
Table 8.7 ROW Pharmacovigilance Market Value by Clinical Trials, 2015-
Table 8.8 ROW Pharmacovigilance Market Value by Service Provider Type, 2015-
List of Figures
Figure 1 Serious Adverse Events Reported to FDA
Figure 2 Global Pharmacovigilance Market Size Snapshot
Figure 3 Global Pharmacovigilance Market by Clinical Trials Snapshot
Figure 4 Global Pharmacovigilance Service Provider Type Share (%), 2015 and
Figure 5 Global Pharmacovigilance Market by Geography Snapshot
Figure 1.1 Global Pharmacovigilance Market Scope
Figure 1.2 Top Down and Bottom up Approach for Market Estimation
Figure 1.3 Average Cost/FTE/Region Case Processing Trend Analysis
Figure 2.1 Objectives of Pharmacovigilance
Figure 2.2 Pharmacovigilance Evolution
Figure 2.3 Need for Pharmacovigilance
Figure 2.4 ADEs Types
Figure 2.5 Number of Deaths due to various causes in the U.S. (2013)
Figure 2.6 Types of Medication Errors
Figure 3.1 Market Dynamics Snapshot
Figure 3.2 YoY growth of Adverse Events (2011-14)
Figure 3.3 Parameters for Safety Concerns
Figure 4.1 Pharmacovigilance Market Development Trends Share Analysis
Figure 4.2 Porter’s Five Forces Analysis for Global Pharmacovigilance Market
Figure 5.1 Pharmacovigilance Value Chain
Figure 6.1 Clinical Trial Phases in Drug Development Process
Figure 6.2 Key Preclinical Pharmacovigilance Services
Figure 6.3 Phase I-IV Pharmacovigilance Services
Figure 6.4 Pharmacovigilance Opportunity Matrix for Clinical Trials
Figure 6.5 Preclinical Safety Evaluation: Considerations
Figure 6.6 Preclinical Safety Evaluation Elements
Figure 6.7 Preclinical Safety Evaluation Primary Goals
Figure 6.8 Key Preclinical Pharmacovigilance Services Providers
Figure 6.9 Phase I Clinical Trial Process
Figure 6.10 Phase I Data Collection Parameters
Figure 6.11 Key Phase I Pharmacovigilance Services Providers
Figure 6.12 Phase II Clinical Trial Primary Goals
Figure 6.13 Key Phase II Pharmacovigilance Services Providers
Figure 6.14 Phase III Clinical Trial Primary Goals
Figure 6.15 Key Phase III Pharmacovigilance Services Providers
Figure 6.16 Phase IV Clinical Trial Primary Goals
Figure 6.17 Key Phase IV Pharmacovigilance Services Providers
Figure 7.1 Key Benefits of Outsourcing PV Activities
Figure 7.2 Pharmacovigilance Opportunity Matrix for Service Provider Type
Figure 7.3 Key In-House Pharmacovigilance Services Providers
Figure 7.4 Key Outsourcing Pharmacovigilance Services Providers
Figure 8.1 Global PV Market Geographical Segmentation
Figure 8.2 Pharmacovigilance Opportunity Matrix for Different Regions
Figure 8.3 Pharmacovigilance Market Value Snapshot by Geography, 2015-
Figure 8.4 Evolution of FDA Pharmacovigilance Activities and Requirements
Figure 8.5 Key Changes in the PV Legislation of Europe

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report